Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Allergan entered into a licensing agreement with AstraZeneca to obtain worldwide rights to the MEDI2070 inflammatory disorder development program, an…
AstraZeneca inks an up-to-$1.5B-plus licensing deal with Allergan for MEDI2070, with $250 million upfront and the balance in milestones, factually framing the…
Jefferies analysts described the AstraZeneca recovery of brazikumab as 'essentially a free new pipeline option,' a positive lens on the asset's terminal value…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AstraZeneca licensed exclusive global rights to MEDI2070 (later brazikumab), a Phase 2b anti-IL-23p19 antibody for Crohn's disease, to Allergan for $250M upfront plus up to $1.27B in milestones plus tiered royalties (~$1.52B total). AstraZeneca passed one-third of payments to Amgen (original co-developer). Allergan later returned rights to AstraZeneca in 2020 to satisfy regulators ahead of AbbVie merger.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Allergan plc (this deal) | 2016 | $1.5B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2016 deals · AstraZeneca PLC deals · Gastroenterology deals